

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

A Randomized Clinical Trial Phase I&II of 3 Times Intrathecal Injections of Umbilical Cord Derived Mesenchymal cells in Children with Spastic Cerebral Palsy 2-14 years old in comparison with control group

Protocol summary

Study aim

This study designed for the evaluation of safety and therapeutic effects of intrathecal injection (ITI) of mesenchymal stem cells (MSC) derived from allogenic umbilical cord in change of developmental functions of spastic cerebral Palsy (CP) in comparison with control group .

Design

Two arm parallel group , double blind ,blocked randomized controlled trial phase 1-2 .

Settings and conduct

70 cases of Spastic CP cases between 2-14 years that have inclusion criteria will be selected and randomly divided in 2 groups of injection of MSC derived from umbilical cord and control of no injection .The trial is double blind and the participants and clinical evaluators are unaware of study groups .

Participants/Inclusion and exclusion criteria

Diparetic , quadriparetic and hemiparetic spastic CP Between the ages of 2-14 years Gross motor function classification (GMFC) between 2 -4 Brain MRI finding compatible with CP Exclusion criteria : Other types of CP Normal brain MRI Uncontrolled seizures Serious diseases of other organs

Intervention groups

Intervention group: Three ITI of MSC every 2 weeks Control group: without injection ,that after needle insertion into the skin without entrance to CSF space needle withdrawn and only simulation of ITI was done without the awareness of the participants . All of the participants had a baseline brain neuroimaging , that will be repeated after 12 months . Patients will be evaluated by predicted scales during the 12 months and will be followed for similar rehabilitation protocol .

Main outcome variables

Motor development alteration by Gross Motor Function Measurement (GMFM 66), Change of motor function by

GMFCS , Change of motor function by Manual Ability Classification System (MACS), Change of motor function by Pediatric Disability Inventory (PEDI) Score, Spasticity change by Ashworth Scale , Change of quality of life (QOL) by CP QOL Questionnaire

General information

Reason for update

Acronym

MSCCP

IRCT registration information

IRCT registration number: **IRCT20110628006907N14**

Registration date: **2020-03-11, 1398/12/21**

Registration timing: **prospective**

Last update: **2020-03-11, 1398/12/21**

Update count: **0**

Registration date

2020-03-11, 1398/12/21

Registrant information

Name

Mahmoudreza Ashrafi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 6612 9252

Email address

ashrafim@tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-04-20, 1399/02/01

Expected recruitment end date

2022-04-20, 1401/01/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

A Randomized Clinical Trial Phase I&II of 3 Times Intratechal Injections of Umbilical Cord Derived Mesenchymal cells in Children with Spastic Cerebral Palsy 2-14 years old in comparison with control group

Public title

Effects of umbilical cord derived mesenchymal stem cells injection in the treatment of children with cerebral palsy

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Spastic cerebral palsy (Dip , Quadri, Hemiparetic) Ages between 2 - 14 years Gross motor function classification (GMFC) 2 -4 No seizure disorder or with controlled seizure Acquired brain MRI finding compatible with CP Informed consent of parents

Exclusion criteria:

Normal brain MRI Progressive neurological diseases Congenital brain cortical malformations TORCH infections(Toxoplasmosis, Others, Rubella Cytomegalovirus Hepatitis C) Other types of cerebral palsy (athetoid , atonic , ataxic , mixed) Acute infections (Human Immunodeficiency Virus , Hepatitis C Virus) Hemorrhagic diathesis Severe anemia (Hemoglobin less than 8) Ventilator dependent pulmonary diseases Severe renal dysfunction Severe liver dysfunction

Age

From **2 years** old to **14 years** old

Gender

Both

Phase

1-2

Groups that have been masked

- Participant
- Care provider
- Outcome assessor
- Data analyser

Sample size

Target sample size: **70**

Randomization (investigator's opinion)

Randomized

Randomization description

The patients are randomly allocated into two groups of intervention and control using a balanced block randomization technique. To do that, they were divided into blocks of 6 and 9. All subjects randomly allocated with online randomization software to generate random-number sequences. {Sealed Envelope Ltd. 2015. Create a blocked randomization list. [Online] Available from: <https://www.sealedenvelope.com/simple-randomiser/v1/lists> [Accessed 15 Dec 2015]}. Coordinator and Physician

responsible for assessing inclusion / exclusion criteria and registering individuals are blind.

Blinding (investigator's opinion)

Double blinded

Blinding description

As this study designed as double blind , In the control group after insertion of the needle into the skin with an appearance of simulating of lumbar puncture no injection were done without the awareness of the patients or their parents and clinical evaluators . At the end of the study if safety and effectiveness of cell therapy will be proved , for ethical consideration cell therapy will be performed for control group .

Placebo

Used

Assignment

Parallel

Other design features

Designing of 3 injection of stem cells with defined interval in intervention group - including of hemiparetic CP in the study

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Tehran University of Medical Sciences

Street address

No 226, Central organization, Ghods Street, Keshavarz Boulvar

City

Tehran

Province

Tehran

Postal code

1417653761

Approval date

2020-02-11, 1398/11/22

Ethics committee reference number

IR.TUMS.VCR.REC.1398.932

Health conditions studied

1

Description of health condition studied

Spastic Cerebral Palsy

ICD-10 code

G80

ICD-10 code description

Cerebral palsy

Primary outcomes

1

Description

Motor development alteration with GMFM 66 score

Timepoint

Before intervention , 3 months after first intervention ,6 months after first intervention , 12 months after first intervention

Method of measurement

GMFM 66 score Questionnaire

2

Description

Change of motor function with GMFCS score

Timepoint

Before intervention , 3 months after first intervention ,6 months after first intervention , 12 months after first intervention

Method of measurement

GMFCS Questionnaire

3

Description

Change of motor function according to PEDI score

Timepoint

Before intervention , 3 months after first intervention ,6 months after first intervention , 12 months after first intervention

Method of measurement

PEDI Questionnaire

4

Description

Change of motor function according to MACS score

Timepoint

Before intervention , 3 months after first intervention ,6 months after first intervention , 12 months after first intervention

Method of measurement

MACS Questionnaire

5

Description

Spasticity change of patients according to Ashworth scale

Timepoint

Before intervention , 3 months after first intervention ,6 months after first intervention , 12 months after first intervention

Method of measurement

Ashworth Questionnaire

6

Description

Change of quality of life

Timepoint

Before intervention , 6 months after first intervention , 12 months after first intervention

Method of measurement

CPQOL Questionnaire

Secondary outcomes

1

Description

Probable Change of brain lesions

Timepoint

Before intervention , 1 year after first intervention

Method of measurement

Brain Magnetic Resonance Imaging (MRI), Brain Magnetic Resonance Spectroscopy (MRS) , Brain Deep Tensor Imaging (DTI)

2

Description

Number of participants experiencing adverse effects and serious adverse effects

Timepoint

First 24 hours after injection and then any time if occurred

Method of measurement

Questionnaire , parents report and periodic planned clinical evaluations

Intervention groups

1

Description

Intervention group : CP patients receiving ,three intrathecal injection of 20 millions allogenic mesenchymal stem cells derived from umbilical cord , prepared by Cell Thec Pharmed Company. Interval of injections is every 2 weeks . Intrathecal injection will be done under anesthesia via lumbar puncture . After taking 3-5 milliliter of cerebrospinal fluid , 2 milliliter prepared stem cells will be injected with a syringe . The patient will be admitted for one day for monitoring of probable adverse reactions . One year followup and evaluation with regular similar rehabilitative therapy will be done .

Category

Treatment - Drugs

2

Description

Control group : CP patients without injection , that after insertion of needle into the skin without entering into the cerebrospinal fluid space , needle will be withdrawn without any injection and only with an appearance of simulation of lumbar puncture without the awareness of the patient or their parents. The patient will be admitted one day for monitoring of probable adverse reaction . One year followup and evaluation with regular similar rehabilitative therapy will be done .

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Children's Medical Center Hospital

Full name of responsible person

Reza Shervin Badv

Street address

Children's Medical Center Hospital , No 62 , Gharib Street , end of keshavarz Blvd

City

Tehran

Province

Tehran

Postal code

1419733151

Phone

+98 21 6692 9234

Fax

Email

drbadv@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Mohammad Ali Sahraeian

Street address

No 226, Central organization, Ghods Street, Keshavarz Boulvar

City

Tehran

Province

Tehran

Postal code

1417653761

Phone

+98 21 8898 7381

Email

msahrai@tums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Tehran University of Medical Sciences

Proportion provided by this source

1

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

2

Sponsor

Name of organization / entity

ROYAN stem cell technology Co

Full name of responsible person

Morteza zarrabi

Street address

No. 24, East Hafez Alley, Bani Hashim Square, Bani Hashim St, Resalat Highway, Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1665666311

Phone

+98 21 8978 1307

Email

info@rsct.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

ROYAN stem cell technology Co

Proportion provided by this source

99

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Persons

Person responsible for general inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Anahita Majmaa

Position

Pediatrician

Latest degree

Subspecialist

Other areas of specialty/work

Pediatrics

Street address

Children's Medical Center Hospital , No 62 , Gharib Street , End of Keshavarze Blvd , Tehran

City

Tehran

Province

Tehran

Postal code
1419733151
Phone
+98 21 6612 9252
Fax
+98 21 6612 9252
Email
majmaaa911@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Mahmoud Reza Ashrafi
Position
Professor
Latest degree
Subspecialist
Other areas of specialty/work
Neurology
Street address
Children's Medical Center , No 62 , Gharib Street , End of Keshavarz Blvd , Tehran
City
Tehran
Province
Tehran
Postal code
1419733151
Phone
+98 21 6612 9252
Fax
+98 21 6612 9252
Email
mr_ashrafi@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Morteza Heidari
Position
Assistant professor
Latest degree
Subspecialist
Other areas of specialty/work

Neurology
Street address
Children's Medical Center , No 62 , Gharib Street , End of Keshavarz Blvd , Tehran
City
Tehran
Province
Tehran
Postal code
1419733151
Phone
+98 21 6612 9252
Fax
+98 21 6612 9252
Email
mortezah93@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Title and more details about the data/document

All collected deidentified IPD can be shared

When the data will become available and for how long

6 months after publication

To whom data/document is available

People working in academic institutions and people working in businesses

Under which criteria data/document could be used

Planning of similar studies in other academic centers

From where data/document is obtainable

Email address

What processes are involved for a request to access data/document

After request during the 1-2 months

Comments